PMID- 30869117
OWN - NLM
STAT- MEDLINE
DCOM- 20200923
LR  - 20201112
IS  - 1527-330X (Electronic)
IS  - 1090-820X (Print)
IS  - 1090-820X (Linking)
VI  - 39
IP  - 12
DP  - 2019 Nov 13
TI  - Injection of an Adipocytolytic Agent for Reduction of Excess Periaxillary Fat.
PG  - NP495-NP503
LID - 10.1093/asj/sjz067 [doi]
AB  - BACKGROUND: The principal current treatment options for reduction of excess 
      anterior periaxillary fat (APAF) are invasive procedures such as excision and 
      liposuction. OBJECTIVES: The aim of this study was to evaluate the efficacy and 
      safety of ATX-101 (deoxycholic acid injection) as a treatment to reduce APAF. 
      METHODS: In this retrospective study, 12 women with periaxillary fullness 
      underwent ATX-101 treatment. Patients were examined to confirm that fullness was 
      due to excess APAF and sufficient subcutaneous fat was present to warrant 
      treatment. Before treatment, the lateral and medial borders of the treatment area 
      were identified and marked. A 1-cm grid was placed to guide the placement of the 
      ATX-101 injections. Reduction in APAF was based on visual assessment and 
      palpation by the clinician, and assessment of before/after patient photographs by 
      the patient and 2 blinded plastic surgeons; all had to agree that APAF reduction 
      had occurred. Patient satisfaction was also assessed. Safety was evaluated in 
      terms of adverse events (AEs). RESULTS: Patients underwent a mean of 1.8 ATX-101 
      treatments; 5 patients received 1 treatment, whereas 7 received multiple 
      treatments. Ten patients achieved a reduction in APAF and were satisfied with 
      treatment. One patient was satisfied after 1 treatment but did not return for 
      posttreatment photographs. One patient did not show any noticeable reduction in 
      APAF after 1 treatment; however, this patient was satisfied and additional 
      treatments are planned. Common AEs included injection-site numbness, edema, and 
      tenderness that lasted for a mean of 18.6, 6.0, and 4.5 days, respectively. 
      CONCLUSIONS: ATX-101 effectively reduced APAF and was generally well tolerated in 
      this small cohort. Larger prospective studies are needed to confirm these 
      findings.
CI  - (c) 2019 The American Society for Aesthetic Plastic Surgery, Inc.
FAU - Shridharani, Sachin M
AU  - Shridharani SM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Aesthet Surg J
JT  - Aesthetic surgery journal
JID - 9707469
RN  - 0 (ATX-101 compound)
RN  - 005990WHZZ (Deoxycholic Acid)
SB  - IM
MH  - Adult
MH  - Axilla
MH  - *Cosmetic Techniques
MH  - Deoxycholic Acid/*administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Injections
MH  - Middle Aged
MH  - Patient Satisfaction
MH  - Retrospective Studies
MH  - Subcutaneous Fat/*drug effects/metabolism
MH  - Time Factors
PMC - PMC7643535
EDAT- 2019/03/15 06:00
MHDA- 2020/09/24 06:00
PMCR- 2019/03/14
CRDT- 2019/03/15 06:00
PHST- 2019/03/15 06:00 [pubmed]
PHST- 2020/09/24 06:00 [medline]
PHST- 2019/03/15 06:00 [entrez]
PHST- 2019/03/14 00:00 [pmc-release]
AID - 5380492 [pii]
AID - sjz067 [pii]
AID - 10.1093/asj/sjz067 [doi]
PST - ppublish
SO  - Aesthet Surg J. 2019 Nov 13;39(12):NP495-NP503. doi: 10.1093/asj/sjz067.